264 related articles for article (PubMed ID: 22962909)
1. Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Guirguis-Blake J
Am Fam Physician; 2012 Jul; 86(1):21-3. PubMed ID: 22962909
[No Abstract] [Full Text] [Related]
2. [Appropriate pharmacological therapy after surgical or percutaneous myocardial revascularization].
Faggiano P; De Feo S; Frattini S; Tramarin R; Dei Cas L
G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):116S-120S. PubMed ID: 20879496
[No Abstract] [Full Text] [Related]
3. Ask the doctor. I had a heart attack three years ago at age 78. My doctor started me on lisinopril, carvedilol, and aspirin. My total cholesterol is 190, and my LDL is 128. Should I be taking a statin?
Lee R
Harv Heart Lett; 2011 Aug; 21(12):7. PubMed ID: 21991614
[No Abstract] [Full Text] [Related]
4. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
[No Abstract] [Full Text] [Related]
5. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
6. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease.
Mancini GB; Gosselin G; Chow B; Kostuk W; Stone J; Yvorchuk KJ; Abramson BL; Cartier R; Huckell V; Tardif JC; Connelly K; Ducas J; Farkouh ME; Gupta M; Juneau M; O'Neill B; Raggi P; Teo K; Verma S; Zimmermann R;
Can J Cardiol; 2014 Aug; 30(8):837-49. PubMed ID: 25064578
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and correlates of cardiovascular medication use among nursing home residents with ischemic heart disease: results from the SHELTER study.
Foebel AD; Liperoti R; Gambassi G; Gindin J; Ben Israel J; Bernabei R; Onder G
J Am Med Dir Assoc; 2014 Jun; 15(6):410-5. PubMed ID: 24559641
[TBL] [Abstract][Full Text] [Related]
8. Drug secondary prevention in postmenopausal women with ischemic heart disease.
Zdrenghea D; Pop D; Sitar-Tăut A; Cebanu M; Zdrenghea V
Rom J Intern Med; 2009; 47(1):41-5. PubMed ID: 19886068
[TBL] [Abstract][Full Text] [Related]
9. [PRoFESS study presented. Change in secondary prevention].
MMW Fortschr Med; 2003 May; 145 Suppl 2():96-7. PubMed ID: 14579494
[No Abstract] [Full Text] [Related]
10. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
Skinner JS; Minhas R
Heart; 2007 Jul; 93(7):864-6. PubMed ID: 17569812
[No Abstract] [Full Text] [Related]
11. Secondary prevention of ischaemic cardiac events.
Gami A
Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
[No Abstract] [Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
14. [Secondary prevention of ischemic cardiopathy].
Caruzzo E; Caruzzo C
Cardiologia; 1995 May; 40(5):347-53. PubMed ID: 8529246
[No Abstract] [Full Text] [Related]
15. Study at up to 700 sites will build on landmark HOPE trial.
Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703
[No Abstract] [Full Text] [Related]
16. Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes.
Crosier R; Austin PC; Ko DT; Lawler PR; Stukel TA; Farkouh ME; Wang X; Spertus JA; Ross HJ; Lee DS
Am J Med; 2021 May; 134(5):672-681.e4. PubMed ID: 33181105
[TBL] [Abstract][Full Text] [Related]
17. Do All Patients Need β-Blockers After a Heart Attack?
Abbasi J
JAMA; 2018 Mar; 319(9):853-855. PubMed ID: 29450492
[No Abstract] [Full Text] [Related]
18. Management of atrial fibrillation.
Kahali D; Mondal S
J Indian Med Assoc; 2012 May; 110(5):297-301. PubMed ID: 23360021
[No Abstract] [Full Text] [Related]
19. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
20. [Unrecognized myocardial infarction].
Matsumoto T
Nihon Rinsho; 2007 Sep; Suppl 5 Pt 2():249-52. PubMed ID: 17952999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
